HBI 2375
Alternative Names: HBI-2375Latest Information Update: 13 Jun 2024
At a glance
- Originator HUYA Bioscience International
- Class Antineoplastics
- Mechanism of Action Protein-protein interaction inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Leukaemia; Solid tumours
Most Recent Events
- 05 Apr 2024 Adverse events, pharmacokinetics and pharmacodynamics data from the preclinical studies in Solid tumours and Leukemia presented at 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 10 Oct 2023 Pharmacokinetics and pharmacodynamics data from a preclinical studies in solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
- 21 May 2022 HUYA Bioscience International plans a clinical trial for HBI 2375